Relationship of peripheral blood mononuclear cells miRNA expression and parasitic load in canine visceral leishmaniasis

Jaqueline Poleto Bragato¹, Larissa Martins Melo¹, Gabriela Lovizutto Venturin¹, Gabriela Torres Rebech¹, Leandro Encarnação Garcia², Flavia Lombardi Lopes², Valéria Marçal Felix de Lima¹*¹

¹ Department of Animal Clinic, Surgery and Reproduction, São Paulo State University (Unesp), School of Veterinary Medicine, Aracatuba, São Paulo, Brazil, ² Department of Support, Production and Animal Health, São Paulo State University (Unesp), School of Veterinary Medicine, Aracatuba, São Paulo, Brazil

* vmflima@fmva.unesp.br

Abstract

Visceral leishmaniasis (VL) in humans is a chronic and often fatal disease if left untreated. Dogs appear to be the main reservoir host for L. infantum infection, however, in many regions other canids such as jackals, foxes, wolves and other mammals, such as hares or black rats, have been implicated as wild reservoirs. Most dogs cannot form an effective immune response against this infection, and this could be modulated by small non-coding RNAs, called microRNAs, responsible for post-transcriptional control of gene expression. Here, we evaluated the expression of miRNAs in peripheral blood mononuclear cells (PBMC) of symptomatic dogs naturally infected with Leishmania (L.) infantum (n = 10) and compared to those of healthy dogs (n = 5). Microarray analysis revealed that miR-21, miR-424, miR-194 and miR-451 had a 3-fold increase in expression, miR-192, miR-503, and miR-371 had a 2-fold increase in expression, whereas a 2-fold reduction in expression was observed for miR-150 and miR-574. Real-time PCR validated the differential expression of miR-21, miR-150, miR-451, miR-192, miR-503, and miR-371 had a 2-fold increase in expression, whereas a 2-fold reduction in expression was observed for miR-150 and miR-574. Real-time PCR validated the differential expression of miR-21, miR-150, miR-451, miR-192, miR-194, and miR-371. Parasite load of PBMC was measured by real-time PCR and correlated to the differentially expressed miRNAs, showing a strong positive correlation with expression of miR-194, a regular positive correlation with miR-371 expression, and a moderate negative correlation with miR-150 expression in PBMC. These findings suggest that Leishmania infection interferes with miRNAs expression in PBMC, and their correlation with parasite load may help in the identification of therapeutic targets in Canine Visceral Leishmaniasis (CVL).

Introduction

Visceral Leishmaniasis (VL) is a zoonosis caused by the protozoan Leishmania infantum and is the most fatal form of this parasitic disease [1]. Despite occurring in 76 countries, VL is still one of the most neglected diseases in the world and, of the human cases reported in America, 95.1% are in Brazil [2]. Dogs are considered the main domestic reservoirs of L. infantum [3].
Once in the vertebrate host, the parasite may cause lesions and symptoms that are characteristic of Canine Visceral Leishmaniasis (CVL), although some infected dogs may be oligo or asymptomatic [4], others may evolve to spontaneous cure [5]. The most frequent signs of VL are lymphadenopathy, onychogryphosis, cutaneous lesions, weight loss, cachexia, fever and locomotor abnormalities [6].

Protective immunity in dogs has generally been associated with a cellular immune response manifested by a positive lymphoproliferative response to Leishmania spp antigens [7] and cytokine production, such as IFN-γ and TNF-α, which are necessary for macrophage activation and parasite death [8]. The role of T cell in the induction of the cellular response is determinant for the elimination of the parasite inside the macrophages [9].

In recent years, microRNAs (miRNAs) have been shown to play a critical role in the development and function of immune responses [10]. miRNAs are a group of small, highly conserved, single-stranded non-coding RNAs that regulate gene expression at the post-transcriptional level [11].

*In vitro* infection of human phagocytes with *Leishmania donovani* showed that the parasite induces alteration on the expression of miR-21, miR-155 and miR-146b-5p and interferes with the TGF-β signaling pathway [12]. *In vitro* infection of J774 murine macrophages with *L. infantum* increases miR-155, which in turn plays a role in regulating the response to *L. infantum* [13]. In BALB/c mice infected with *L. donovani*, there is a decrease in miR-122 expression, facilitating hepatic infection, and an increase in miR-122 expression decreases parasite burden in the liver [14]. *Leishmania donovani* infected mice macrophages have altered expression of miR-3620, miR-6385, miR-6973a, miR-6996, miR-328, miR-8113, miR-3473f, miR-763, miR-6540 and miR-1264, that are involved in controlling macrophage effector functions [15]. An *in silico* study has also shown that miR-29a and miR-29b target signal transcription factors that play a role in the proliferation and differentiation of T cells in visceral leishmaniasis in human, indicating that miRNAs can regulate immune response and infection control [16]. Although there are several studies on the role of miRNAs in VL, the expression of miRNAs in infected dogs, the most important reservoir for *Leishmania*, has not yet been described.

In this study, we demonstrated that there are differences in the expression of miRNAs in PBMC of dogs with VL compared to healthy dogs. The parasite load showed strong positive correlation with the miR-194 expression and regular correlation with miR-371 and miR-150 expressions in PBMC.

**Materials and methods**

**Screening of animals and collection of samples**

This study was approved by the Committee of Ethics in Animal Experimental Research (COBEA), with the approval of the Institutional Animal Care and Use Committee of UNESP–Universidade Estadual Paulista "Júlio de Mesquita Filho"—Aracatuba—School of Veterinary Medicine—FMVA (process 00978/2016). The generation of the dataset analysed within this manuscript is available in a data descriptor article [17].

Five healthy animals from an endemic area (Aracatuba-SP, Brazil) with absence of parasitic DNA by PCR, upon clinical examination, complete blood count and serum biochemical profile evaluation, were selected for this study, and ten animals naturally infected with *Leishmania infantum*, from the Zoonosis Control Center of Aracatuba, were selected. These animals contained at least three characteristic clinical signs of the disease, including onychogriphosis, weight loss, ear-tip injuries, periorbital lesions, alopecia, skin lesions and lymphadenopathy (S1 Table). Blood samples from both groups (infected and healthy) were collected in tubes without EDTA to obtain serum for biochemical profile (S2 Table) and indirect ELISA assay.
(S1 Table) for the detection of anti-leishmania antibodies [18], and in EDTA tubes for complete blood count (CBC) (S3 Table) and isolation of the PBMC. Based on clinical signs, CBC results and biochemical profile, infected animals were classified in the clinical stage II of the disease [19]. PCR for detection of *Leishmania* DNA from PBMC cells was performed for all animals. Infected animals were euthanized by barbiturate anesthesia (Tiopental, Cristália Itapira, SP), followed by intravenous injection of potassium chloride 19.1% by the same route, in compliance with local laws.

**Isolation of peripheral blood mononuclear cells**

PBMC were isolated by gradient Histopaque 1077 (Sigma-Aldrich) following manufacturer’s instructions. They were then washed twice in phosphate buffered saline solution at pH 7.2. After isolation, these cells were counted in a Neubauer chamber for further extraction of DNA and total RNA containing the miRNAs.

**DNA extraction and determination of the *Leishmania* species**

DNA extraction from PBMC samples from the experimental dogs was performed using 5x10^6 cells with the commercial DNAeasy kit (Qiagen) according to the manufacturer’s recommendations. Extracted DNA was quantified in spectrophotometer 260/280 (NanoDrop, Thermo Fisher Scientific) for evaluation of purity and concentration, and were then stored at -20˚C until analysis.

Determination of the *Leishmania* species was performed by PCR-RFLP (Restriction Fragment Length Polymorphism) [20], comparing the restriction profiles of the sample with a PCR restriction profile obtained from *L. infantum* (IOC / L0575-MHOM / BR / 2002 / LPC-RPV), *L. braziliensis* (IOC / L0566-MHOM / BR / 1975 / M2903) and *L. amazonensis* (IOC / L0575-MHOM / BR / 1967 / PH8) as positive controls, and water as a negative control.

**Quantification of the parasite load by real-time PCR**

DNA extraction from PBMC samples from the experimental dogs was performed using 5x10^6 cells with the commercial DNAeasy kit (Qiagen) according to manufacturer’s recommendation.

Parasite load quantification was performed by real-time PCR with a final reaction volume of 20μL using primers amplifying a 116bp fragment of the kinetoplast DNA (kDNA) of *Leishmania* spp. (5’ CCTATTTTACCAACACCCAGT 3’ and 5’ GGGTAGGGCGTCTCCTC 3’), at a concentration of 900nM [21], Power SYBR Green PCR Master Mix (Applied Biosystems) and 50ng of sample DNA. Amplification condition used was comprised of an initial heating of 95˚C for 10 minutes, 40 cycles of 95˚C for 15 seconds and 65˚C for 60 seconds. Upon the end of amplification, a dissociation curve of the amplified fragment was determined from 60˚C to 95˚C with an increase of 0.5˚C every 5 seconds. A standard curve with DNA from *Leishmania infantum* promastigotes (MHOM/BR00/MER02) with a serial dilution of 10^8 to 10^1 of parasite DNA was performed for each reaction.

**Extraction and quantification of miRNA**

Extraction of total RNA from 5x10^6 PBMC was performed on the samples with the commercial mirVana kit for isolation of miRNA with phenol (Life Technologies), following the procedure indicated by the manufacturer. Following isolation, total RNA was stored at -80˚C until evaluation of quality and concentration.
Isolated RNAs were analyzed by spectrophotometry (NanoDrop, Thermo Fisher Scientific) for evaluation of their quantity and purity (260/280). Before performing microarray, samples were also analyzed for RNA quality by capillary electrophoresis (Bioanalyzer, Agilent Technologies) using the commercial Agilent RNA 6000 Nano kit, following manufacturer’s instructions.

**Microarray**

Total RNAs with satisfactory amount (over than 30ng/μl) and quality (RNA integrity number > 8) were used to perform microarray analysis using a miRNA 4.1 Array Strip (Affymetrix) containing probes designed for the miRNAs of several species, including 291 from *Canis familiaris*.

MicroRNAs were biotinylated using the Affymetrix FlashTag Biotin HSR RNA Labeling Kit following manufacturer’s instructions. For the microarray, GeneAtlas Hybridization, Wash, and Stain Kit for miRNA array Strips were used, following manufacturer’s instructions.

Microarray data were deposited in Gene Expression Omnibus with the access number GSE105443 according to the minimum information about microarray experiment (MIAME) standards.

**Microarray data analysis**

Normalization and quality of microarray analysis of the miRNAs of control and infected dogs were performed in the Expression Console Software program, version 1.4.1 (Affymetrix, Thermo Fisher Scientific). Differential analysis of the miRNAs was performed in the Transcriptome Analysis Console (Affymetrix, Thermo Fisher Scientific).

The miRBase database (mirbase.org) was used to check the homology between the sequences of all differentially expressed non-canine miRNAs with known canine miRNAs.

Analysis of targets and pathways for the differentially expressed and validated miRNAs in dogs with VL were performed using the Ingenuity Pathway Analysis program (Qiagen).

Gene Ontology (GO) enrichment analysis was performed using the ENRICHR program (http://amp.pharm.mssm.edu/Enrichr/) [22,23].

**Real-time PCR for miRNAs analysis**

To validate the results obtained by microarray, real-time PCR (qPCR) was performed. cDNA production was performed using the miScript RT II kit (Qiagen), as recommended by the manufacturer. qPCR reactions were performed using commercially available specific primers for our *Canis familiaris* miRNAs of interest and the endogenous reference SNORD96A (miScript, Qiagen) using the SYBR Green system (miScript SYBR Green PCR kit, Qiagen) in real-time thermal cycler (RealPlex, Eppendorf). Amplification conditions were determined by the manufacturer. All miRNAs (including the reference) were run in separate plates. For each miRNA, a standard curve with a serial dilution of a pool of the cDNAs was performed. Absolute quantification of each miRNA was performed by converting sample cycle threshold values to a concentration (ng/μl), based on the standard curves, which were generated using 10-fold serial dilutions of the pool of cDNAs. Target amount was then divided by SNORD96A levels to obtain a normalized target value. All samples were evaluated in duplicate.

**Statistical analysis**

Statistical analysis were performed using the GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). Analysis of variance (ANOVA) was performed for treatment
comparison in the microarray. Mann-Whitney test was performed for the miRNA qPCR results. Spearman correlation was done to evaluate the association between miRNA expression and blood count, biochemical molecules and parasite load. Fisher test was used by IPA for canonical pathway analysis. Results were considered significant when p<0.05.

Results

*Leishmania infantum* was identified in dogs with VL

PCR-RFLP was performed to identify the *Leishmania* species. In all dogs of the infected group, *L. infantum* was found as the causative agent, as shown in S1 Fig.

Differentially expressed microRNAs and validation in PBMC of dogs with VL compared to healthy dogs

Considering that miRNAs can regulate immune response [11], microarray was employed for comparative analysis of miRNA expression in the blood of dogs naturally infected with *L. infantum* and healthy dogs. miRNAs miR-194, miR-192, miR-21, miR-424, miR-451, miR-503 and miR-371 showed increased expression in the blood of infected dogs (3.1, 2.8, 3.7, 3.2, 3.1, 2.0 and 2.9 fold change respectively), while miR-150 and miR-574 showed decreased blood expression (-2.2 and -2.7 fold change respectively). S4 Table shows canine differentially expressed miRNAs in dogs with VL and respective fold change and p-value. Heatmap (Fig 1A) and Volcano plot (Fig 1B) show the differentially expressed miRNAs in PBMC of dogs with VL compared to healthy ones. miRNAs of other species (mammals, birds, fish, plants) hybridized in the microarray, but none of them showed homology with currently described canine sequences. The percentage of upregulated canine miRNAs was 2.40% (7/291) and downregulated was 0.68% (2/291).

To confirm the differential expression of miRNAs in the blood of dogs with VL in the microarray, real-time PCR validation was performed. Reactions showed efficiency from 0.84 to 1.42, slope from -2.603 to 3.761 and R² from 0.933 to 0.998 (S5 Table).

miR-21, miR-451, miR-192, miR-194 and miR-371 were increased similarly to the results seen for the microarray, and miR-150 decreased in the PBMC (Fig 1C).

Canonical pathways regulated by differentially expressed miRNAs in PBMC of infected animals

IPA’s microRNA Target Filter (employing highly predicted and experimentally observed only) showed target genes and demonstrated 63 canonical pathways regulated by these miRNAs/targets (S6 Table). The top 20 canonical pathways and target genes are presented in Table 1, including p53 signaling, antiproliferative role of TOB in T cell signaling, STAT3 pathway, PTEN signaling, death receptor signaling and crosstalk between dendritic cells and natural killer cells, that can regulate the immune response in CVL. We further showed the canonical pathway “crosstalk between dendritic cells and natural killer cells” (Fig 2), which targets important genes involved in immunopathogenesis in CVL, such as NFκB, TNF-α, CD80, IFN-γ and DNAM-1.

To understand the functional networks of the target genes, GO analysis was performed. GO analysis showed that these target genes were involved in a large number of physiological processes at the levels of biological processes, cellular component and molecular function (S7–S9 Tables).
Blood count, biochemical molecules and correlation with the expression of microRNAs miR-194 and miR-371 in dogs naturally infected with *L. infantum*

There was a strong positive correlation between miR-194 expression and serum urea ($r = 0.73 \ p = 0.031$) (S2A Fig). There was a strong negative correlation between miR-194 expression and hemoglobin concentration ($r = -0.70 \ p = 0.037$) (S2B Fig) and a strong negative correlation between miR-371 expression and globular volume (S2C Fig) ($r = -0.76 \ p = 0.019$).
### Table 1. Top twenty canonical pathways predicted for the differentially regulated miRNAs in CVL.

| Ingenuity Canonical Pathways                              | P value  | miRNAs in the Pathway | Target genes                                                                 |
|-----------------------------------------------------------|----------|------------------------|------------------------------------------------------------------------------|
| Aryl Hydrocarbon Receptor Signaling                       | 0.00014  | miR-150                | CDKN1B, CHEK2, HSP90B1, IL1A, TNF, TP53                                      |
|                                                            |          | miR-192                | ATM, DHFR, FASLG, GSTA2, RB1                                                 |
|                                                            |          | miR-194                | ALDH4A1, GSTT2, IL1A, MAPK1                                                  |
|                                                            |          | miR-21                 | ALDH1A1, APAF1, CD6, CDKN1A, FAS, FASLG, IL1B, NFIA, NFIB, TNF               |
| p53 Signaling                                             | 0.00015  | miR-150                | CHEK2, MDM4, PERP, TP53                                                     |
|                                                            |          | miR-192                | ATM, PERP, RB1, STAG1                                                       |
|                                                            |          | miR-194                | CCNG1, CSNK1D, SERPINE2, THBS1                                              |
|                                                            |          | miR-21                 | APAF1, CCNG1, CDKN1A, FAS, FRS2, PIK3R1, PTEN, SERPINB5, TNFRSF10B          |
| Tumoricidal Function of Hepatic Natural Killer Cells      | 0.00030  | miR-150                | GZMB                                                                         |
|                                                            |          | miR-192                | CYCS, FASLG                                                                 |
|                                                            |          | miR-194                | CASP7, SRGN                                                                 |
|                                                            |          | miR-21                 | APAF1, CASP8, FAS, FASLG                                                    |
| Osteoarthritis Pathway                                    | 0.00068  | miR-150                | CEBPB, CREB1, MMP13, TNF, VEGFA                                             |
|                                                            |          | miR-192                | ADIPQ, FGF2, HTRA1, IL1RAP, SDC4, TGFBR1                                    |
|                                                            |          | miR-194                | CASP7, FZD6, RAC1                                                            |
|                                                            |          | miR-21                 | BMPR2, CASP8, FGF18, FZD6, GLI2, IL1B, JAG1, R8BP, SMAD7, TGFBR2, TIMP3,  |
|                                                            |          |                        | TNF, VEGFC                                                                  |
| Hepatic Fibrosis / Hepatic Stellate Cell Activation       | 0.00098  | miR-150                | IL1A, MMP13, PDGFBR, STAT1, TNF, VEGFA                                      |
|                                                            |          | miR-192                | CCR5, CSF1, FASLG, FGF2, FLT1, IL1RAP, SERPINE1, TGFBR1                    |
|                                                            |          | miR-194                | CXCL3, EDN1, IL1A                                                            |
|                                                            |          | miR-21                 | ACTA2, CCR7, FAS, FASLG, IL1B, IL6R, KLF6, SMAD7, TGFBR2, TNF, TGFBR1,  |
|                                                            |          |                        | VEGFC                                                                       |
| Crosstalk between Dendritic Cells and Natural Killer Cells| 0.00141  | miR-150                | CD226, TNF                                                                  |
|                                                            |          | miR-192                | CD80, FASLG                                                                 |
|                                                            |          | miR-194                | ACTG2, CD83, FSCN3                                                           |
|                                                            |          | miR-21                 | ACTA2, CCR7, CD69, FAS, FASLG, IL12A, TNF                                    |
| dTMP De Novo Biosynthesis                                 | 0.00182  | miR-192                | DHFR, DHFR2, TYMS                                                            |
| Cell Cycle: G1/S Checkpoint Regulation                    | 0.00186  | miR-150                | CDKN1B, HDAC8, SKP1, TP53                                                   |
|                                                            |          | miR-192                | ATM, RB1                                                                    |
|                                                            |          | miR-194                | BM11, E2F6, HDAC8                                                           |
|                                                            |          | miR-21                 | CDC25A, CD6, CDKN1A                                                         |
| STAT3 Pathway                                             | 0.00347  | miR-192                | FLT1, PIM1, SOCS6, TGFBR1                                                   |
|                                                            |          | miR-194                | MAPK1, RAC1, RRAS2, SOCS2                                                   |
|                                                            |          | miR-21                 | BMPR2, CDC25A, CDKN1A, MAPK1, SOCS5, SOCS6, STAT3, TGFBR2                   |
| Human Embryonic Stem Cell Pluripotency                    | 0.00363  | miR-150                | FOXD3, PDGFB                                                                |
|                                                            |          | miR-192                | ATM, FGF2, LEFTY2, TGFBR1                                                   |
|                                                            |          | miR-194                | ACVR1, FZD6, H2BFM                                                          |
|                                                            |          | miR-21                 | BMPR2, FRS2, FZD6, NTF3, PIK3R1, SMAD7, SOX2, TGFBR2                         |
| Estrogen-mediated S-phase Entry                            | 0.00417  | miR-150                | CDKN1B                                                                      |
|                                                            |          | miR-192                | RB1                                                                         |
|                                                            |          | miR-194                | E2F6                                                                        |
|                                                            |          | miR-21                 | CDC25A                                                                      |
| Actin Cytoskeleton Signaling                              | 0.00427  | miR-150                | ARPC3, FGF16, PDGFB, TMSB4                                                  |
|                                                            |          | miR-192                | ATM, BRK1, CRK, FGF14, FGF2, FGF7, MSN, MYLK, PIP4K2B                        |
|                                                            |          | miR-194                | ACTG2, CEL2, GNA13, LIMK2, MAPK1, FN2, PIP4K2C, RAC1, RRAS2, TMSB4          |
|                                                            |          | miR-21                 | ACTA2, ARHGAP24, ARHGEF12, CFL2, FGF18, FRS2, PIK3R1, PIK3R1, SOX2,  |
|                                                            |          |                        | TIAM1, TMSB4                                                                |

(Continued)
Parasite load on PBMC and correlation with expression of microRNAs

miR-194, miR-371 and miR-150 in dogs naturally infected with *L. infantum*

Real-time PCR reaction for quantification of parasite load presented efficiency values of 0.97, slope -3.405 and $R^2$ 0.958. Parasite load ranged from 10.1ng to 28633ng.

There was a strong positive correlation between parasite load and miR-194 expression ($r = 0.816 \ p = 0.007$) and a regular positive correlation between parasite load and miR-371 expression ($r = 0.683 \ p = 0.042$) in PBMC from infected dogs compared to healthy dogs. There was a regular negative correlation between parasite load and the expression of miR-150 ($r = -0.683 \ p = 0.042$) in these cells. Fig 3 illustrates the correlations between these miRNAs and parasite load.

### Table 1. (Continued)

| Ingenuity Canonical Pathways                      | P value | miRNAs in the Pathway                      | Target genes                                                                 |
|-------------------------------------------------|---------|--------------------------------------------|-----------------------------------------------------------------------------|
| Type I Diabetes Mellitus Signaling              | 0.00427 | miR-150                                    | GZMB, STAT1, TNF                                                             |
|                                                 |         | miR-192                                    | CD80, CYCS, FASLG, GAD1, HLA-DOB, IL1RAP, SOCS6                            |
|                                                 |         | miR-194                                    | GAD1, MAPK1, SOCS2, TRAF6                                                   |
|                                                 |         | miR-21                                     | APAFI1, CASP8, FAS, FASLG, IL12A, IL1B, MAP2K3, MAPK10, SOCS5, SOCS6, TNF, TFNFRSF11B |
| Cyclins and Cell Cycle Regulation               | 0.00437 | miR-150                                    | CDKN1B, HDAC8, SKP1, TP53                                                   |
|                                                 |         | miR-192                                    | ATM, PPP2CB                                                                 |
|                                                 |         | miR-194                                    | E2F6, HDAC8                                                                 |
|                                                 |         | miR-21                                     | CDC25A, CDK6, CDKN1A, SKP2                                                  |
| Regulation of the Epithelial-Mesenchymal Transition Pathway | 0.00468 | miR-150                                    | FGF16, ZEB1                                                                  |
|                                                 |         | miR-192                                    | ATM, FGF14, FGF2, FGF7, TGFBR1, ZEB1, ZEB2                                 |
|                                                 |         | miR-194                                    | FZD6, MAPK1, RRAS2                                                          |
|                                                 |         | miR-21                                     | FGF18, FRS2, FZD6, JAG1, MAP2K3, PIK3R1, RBPJ, SOS2, STAT3, TGFBR2          |
| Antiproliferative Role of TOB in T Cell Signaling | 0.00525 | miR-150                                    | CDKN1B, SKP1                                                                |
|                                                 |         | miR-192                                    | PABPC4, RB1, TGFBR1                                                         |
|                                                 |         | miR-194                                    | MAPK1                                                                      |
|                                                 |         | miR-21                                     | SKP2, TGFBR2                                                               |
| Molecular Mechanisms of Cancer                  | 0.00603 | miR-150                                    | CDKN1B, CHEK2, RAPGEF3, TP53                                               |
|                                                 |         | miR-192                                    | ATM, CRK, CYCS, FASLG, PRKAR1A, PRKCO, RALB, RB1, TGFBR1, XIAP             |
|                                                 |         | miR-194                                    | ADCY7, CASP7, CDK14, E2F6, FBNP1, FZD6, GNA13, H2BFM, MAPK1, PRKAR1A, RAC1, RAP2B, RRAS2 |
|                                                 |         | miR-21                                     | APAFI1, ARHGEF12, BMPR2, CASP8, CDC25A, CDK6, CDKN1A, FAS, FASLG, FRS2, FZD6, PIK3R1, RBPJ, SOS2, STAT3, TGFBR2 |
| PTEN Signaling                                  | 0.00603 | miR-150                                    | CDKN1B                                                                      |
|                                                 |         | miR-192                                    | FASLG, FLT1, TGFBR1                                                         |
|                                                 |         | miR-194                                    | H2BFM, MAPK1, RAC1, RRAS2                                                   |
|                                                 |         | miR-21                                     | BMPR2, CDKN1A, FASLG, PIK3R1, PREX2, PTEN, SOS2, TGFBR2                    |
| Small Cell Lung Cancer Signaling                | 0.00631 | miR-150                                    | CDKN1B, CKS1B, TP53                                                         |
|                                                 |         | miR-192                                    | ATM, CYCS, RB1, TRAF5                                                       |
|                                                 |         | miR-194                                    | CKS1B, MAPK1, RRAS2, TRAF6                                                  |
|                                                 |         | miR-21                                     | APAFI1, CDK6, FRS2, PIK3R1, PTEN, SKP2, SOS2                               |
| Death Receptor Signaling                        | 0.00912 | miR-150                                    | MAPK4K, TNF                                                                 |
|                                                 |         | miR-192                                    | CYCS, FASLG                                                                 |
|                                                 |         | miR-194                                    | XIAP, ACTG2, CASP7, MAPK4K, PARP11                                         |
|                                                 |         | miR-21                                     | ACTA2, APAFI1, CASP8, FAS, FASLG, TNF                                       |

https://doi.org/10.1371/journal.pone.0206876.t001
Fig 2. IPA’s Canonical Pathway “crosstalk between dendritic cells and natural killer cells”. Upregulated miRNAs are in red, and downregulated are in green. Indirect relationships are represented by dotted lines and direct relationships by solid lines. miR-290 is a synonym of miR-371 in IPA’s analysis. miR-192 targets CD80 and FASL. miR-371 targets IL-6 and TNF-α. miR-150 targets TNF-α and DNAM-1. miR-21 targets FAS, FASL, TNFα, CD40L, NFκB, IFNγ, CD69 and CCR7. This figure was obtained with Ingenuity Pathway Analysis (Qiagen).

https://doi.org/10.1371/journal.pone.0206876.g002

Fig 3. Correlation on miRNAs validated by RT-PCR and parasite load in PBMC of dogs infected by L. infantum. Data represents a negative correlation of miR-150 (A) and positive correlation of miR-194 (B) and miR-371 (C).

https://doi.org/10.1371/journal.pone.0206876.g003
Discussion

*Leishmania infantum* was the species observed in dogs with VL in the endemic area studied. Identification of the infecting species is important because differences in miRNA expression by *L. donovani* and *L. major* have already been observed in infected human dendritic cells *in vitro* [12]. Also, *L. amazonensis* has been identified in dogs with visceral leishmaniasis in the nearby city of Bauru-SP, Brazil [20], thus, the determination of *L. infantum* in the samples was important to ensure the subsequent results of the research. We demonstrated by microarray that there was altered expression of nine miRNAs in PBMC of animals with CVL compared to healthy animals; the miRNAs miR-21, miR-192, miR-194, miR-371, miR-503, miR-424 and miR-451 were upregulated, and miR-574 and miR-150 were downregulated in CVL samples. Differentially expressed miRNAs in the microarray in the *Canis familiaris* species were also evaluated by real-time PCR. miR-21, miR-150, miR-451, miR-192, miR-194 and miR-371 qPCR results confirmed the microarray data in PBMC. miR-424, miR-574 and miR-503 showed similar patterns to microarray results, but statistical significance was not achieved, likely due to the small sample size (10 infected animals and 5 healthy animals).

The IPA program was efficient in identifying gene targets and demonstrated 63 canonical pathways regulated by these miRNAs, including p53 signaling, antiproliferative role of TOB in T cell signaling, STAT3 pathway, PTEN signaling, death receptor signaling and crosstalk between dendritic cells and natural killer cells involved in immune response. GO analysis were performed for the predicted target genes of the differentially expressed miRNAs in PBMC from dogs with visceral leishmaniasis. GO analysis results showed that the predicted target genes participated in numerous biological processes, suggesting that the six miRNAs could play important roles in regulation of a variety of biological processes. The results for IPA and GO enrichment analyses can therefore provide direction for future research in canine visceral leishmaniasis.

Canonical pathway “crosstalk between dendritic cells and natural killer cells” involved several target genes of differentially expressed miRNAs and their products, between them, TNF-α and IFN-γ are important cytokines in CVL and are related with disease resistance [8]. The expression of TNF-α and IFN-γ is downregulated by miR 21 [24–26], which would favor parasitic growth [8].

Canonical pathway analysis also showed relation with apoptosis signaling. Fas and FasL, important molecules in apoptosis, were downregulated by miR-21 [27,28]. Expression levels of Fas and FasL in CD4+ cells from blood and spleen have already been shown to be lower in infected dogs when compared to healthy dogs [29], and the soluble levels Fas (sFas) from spleen leukocytes were lower in dogs with VL compared to controls [30]. Thus, miRNAs are acting in apoptosis pathway that occurs in CVL.

miR-21 showed a significant increase in PBMC of animals with CVL (3.7 fold change). This miRNA is involved in immune regulation, negatively regulating the activation of T lymphocytes [31]. Also, it shows a negative correlation with IL-6 and TNF-α production [32]. TNF-α is associated with resistance in CVL, suggesting that the higher levels of miR-21 may be decreasing TNF-α, which in turn could increase parasite load. In addition, miR-21 negatively regulates proteins involved with adaptive immune response generation, CD40L [33], NFKB [34], CD69 [31], CCR7 [35] and a decreased of NFKB [36], CD40L [37], CCR7 [38] were previously observed in *Leishmania* infection in mice, thus suggesting that miR-21 could be modulating these immune regulatory proteins in CVL.

Likewise, miR-192 showed a significant increase in PBMC of animals with CVL, and it has been shown to down regulate immune response in human [39]. *Leishmania* infection in canine monocyte-derived macrophages decreased expression of costimulatory B7 molecules, and the co-culture with B7-transfected cells resulted in the restoration of cell proliferation and IFN-γ
production by a *Leishmania* specific T-cell line [9]. Therefore, it is tempting to suggest that inhibition of T-cell activation and cytokine production are modulated by the expression of miR-192 in dogs with VL.

On the other hand, miR-150 was decreased in PBMC of dogs with VL and had a regular negative correlation with parasitic load in the blood. miR-150 was first described as a key miRNA in the development of B cells [40]. Knockout mice and mutants for miR-150 had an overproduction of immunoglobulins (Igs) of all classes, due to an increase in the number of B1 cells through increased c-Myb gene expression [41]. In dogs with symptomatic VL, there is an increase in the serum level of immunoglobulins of all classes (IgG, IgA IgE, and IgM) [42] and regulatory B cells from *L. infantum*–infected dogs co-cultured with enriched T cells, were sufficient to suppress T cell function through IL-10 and PD1 [43]. It is possible that miR-150 is acting in hypergammaglobulin, and in the development of regulatory B-cells, by increasing the parasite burden due to T-cell suppression in CVL.

Increased parasite load associated with decreased miR-150 could also act in other effector pathways of anti-parasitic immunity. Mutant mice lacking miR-150 have a decrease in the number of mature natural killer (NK) cells, whereas mice with increased expression of this miRNA have enhanced development of NK cells [44]. NK cells may play a role in controlling the burden of *Leishmania* spp. parasites during early stages of infection by their ability to respond rapidly to IFN-γ production, which activates macrophages to kill the parasite. *In vitro*, human NK cells were shown to be directly activated by *Leishmania* promastigotes or their lipophosphoglycan (LPG) to produce IFN-γ [45–47]. Thus, the decrease in NK cells modulated by miR-150 expression could be related to a higher parasite load in the CVL animals.

Unlike miR-150, an increase in miR-194 expression was observed in PBMC in dogs with VL and a positive and strong correlation with parasite blood load was observed. In human THP-1 monocytes, an increase in miR-194 expression directly decreases the expression of the TRAF6 gene, decreasing the release of the proinflammatory cytokine TNF-α [48]. In dogs with asymptomatic VL there is a high expression of TNF-α in lymph nodes with low parasitism, and this expression is lower in symptomatic dogs with a higher parasite load, suggesting that this cytokine has a protective function in *L. infantum* infection [8]. A miR-194 increase in infected dogs could be regulating the secretion of inflammatory cytokines, such as TNF-α, modulating parasite load in these animals.

Moreover, expression of miR-371 is increased in PBMC of dogs with VL and has a positive correlation with parasite load in PBMC. In patients with asthma, miR-371 targets the Runx3 gene and is related to the Th1 and Th2 response balance, and its increased expression is related to a higher Th2 response [49]. In CVL, the response is both Th1 and Th2, but predominantly Th2, with high production of cytokines by these cells, such as IL-10 and TGF-β, and decreased production of Th1-type cytokines [50,51]. Thus, miR-371 could be involved with pathways that regulate Th2 immune response polarization in CVL.

miR-194 showed a strong positive correlation with serum urea of dogs with VL. This miRNA was increased in plasma of rats with renal ischemia–reperfusion injury [52], dogs with VL can present renal failure [53], suggesting that miR-194 could be explored as an early plasma biomarker in renal lesion in dogs with VL.

Further, miR-194 showed a strong negative correlation with hemoglobin concentration and miR-371 showed a strong negative correlation with erythrocyte globular volume. In CVL hemoglobin and globular volume are decreased [54], as observed in our results, and anemia is a common clinical sign observed in complete blood count of dogs with VL [55]. Other miRNAs have been associated with anemia (miR-150-5p, miR-146b-5p and miR-1) [56] and erythroid homeostasis (miR-144 and miR-451) [57], however miR-194 and miR-371 were not associated with anemia, therefore more studies are needed to confirm our results.
Expression of miR-150, miR-194 and miR-371 showed correlation with parasitic load, indicating that target proteins and pathways should be investigated in future studies. Similarly, human macrophages infected with *L. donovani* showed increased expression of miR-30A-3p, and transitory transfection with inhibitor, followed by infection by *L. donovani*, promotes autophagy and decrease parasitic load in these cells [58]. These results indicate that differential expression of miRNA is dependent on the parasite species and infected host, thus emphasizing the need for studies in the canine model, the most important disease reservoir.

These findings suggest that *L. infantum* may modulate miRNAs in naturally infected dogs. We suggest that their role in immune regulation and their correlation to parasite load may help in the identification of therapeutic targets in Canine Visceral Leishmaniasis.

**Supporting information**

**S1 Fig. PCR-RFLP.** Restriction fragment length polymorphism (RFLP) analysis of ITS1-PCR fragments amplified from DNA samples, by using Hae III. M: molecular marker (123 bp); La: *Leishmania amazonensis* (IOC / L0575-MHOM / BR / 1967 / PH8); Lb: *Leishmania braziliensis* (IOC / L0566-MHOM / BR / 1975 / M2903); Li: *Leishmania infantum* (IOC / L0575-MHOM / BR / 2002 / LPC-RPV); 1–10: samples profile identical to *Leishmania infantum*. The restriction fragment length polymorphism (RFLP) are indicated by arrows. (TIFF)

**S2 Fig. Correlation between miRNAs validated by quantitative PCR and complete blood count and biochemical profile of dogs infected by *L. infantum*.** Data shows a positive strong correlation of miR-194 and Urea (A), negative strong correlation of miR-194 and Hemoglobin (B) and negative strong correlation of miR-371 and Globular Volume (C). (TIF)

**S1 Table. Screening of animals.** Optical density on ELISA and clinical signs of naturally infected and healthy animals (control group). (DOCX)

**S2 Table. Biochemical analysis.** Biochemical profile of animals from infected and control group. Abbreviations: ALT (alanine aminotransferase) AST (aspartate aminotransferase) ALP (alkaline phosphatase) GGT (gamma glutamyl transferase). (DOCX)

**S3 Table. Complete blood count.** Blood cells of both infected and control groups. Abbreviations: RBC (red blood cells) GV (globular volume) MCHC (Mean corpuscular hemoglobin concentration) MCV (Mean corpuscular volume) TPP (total plasma protein). (DOCX)

**S4 Table. Differentially expressed canine miRNAs.** Differentially expressed miRNAs of *Canis familiaris* species and respective fold change and p value. (DOCX)

**S5 Table. Validation of miRNA differential expression in CVL by real time PCR.** Values of efficiency and R² on real time PCR to validate differentially expressed miRNAs. (DOCX)

**S6 Table. Ingenuity Canonical Pathways.** Canonical pathways predicted for the differentially regulated miRNAs in CVL. (DOCX)
S7 Table. Top 20 GO Biological Process for the targets of differentially expressed miRNAs in CVL.

(DOCX)

S8 Table. Top 20 GO Cellular Component for the targets of differentially expressed miRNAs in CVL.

(DOCX)

S9 Table. Top 20 GO Molecular Function for the targets of differentially expressed miRNAs in CVL.

(DOCX)

Acknowledgments

The authors would like to thank Flavia Mari Yamamoto for her help with the experiments.

Author Contributions

Conceptualization: Jaqueline Poleto Bragato, Flavia Lombardi Lopes, Valéria Marçal Felix de Lima.

Data curation: Jaqueline Poleto Bragato, Larissa Martins Melo, Gabriela Lovizutto Venturin, Gabriela Torres Rebech, Valéria Marçal Felix de Lima.

Formal analysis: Jaqueline Poleto Bragato, Larissa Martins Melo, Leandro Encarnação Garcia, Valéria Marçal Felix de Lima.

Funding acquisition: Valéria Marçal Felix de Lima.

Investigation: Valéria Marçal Felix de Lima.

Methodology: Jaqueline Poleto Bragato, Larissa Martins Melo, Gabriela Lovizutto Venturin, Gabriela Torres Rebech, Flavia Lombardi Lopes.

Project administration: Valéria Marçal Felix de Lima.

Resources: Jaqueline Poleto Bragato, Larissa Martins Melo, Gabriela Lovizutto Venturin, Gabriela Torres Rebech, Valéria Marçal Felix de Lima.

Software: Jaqueline Poleto Bragato, Leandro Encarnação Garcia, Flavia Lombardi Lopes.

Supervision: Flavia Lombardi Lopes, Valéria Marçal Felix de Lima.

Validation: Jaqueline Poleto Bragato, Larissa Martins Melo, Leandro Encarnação Garcia.

Writing – original draft: Jaqueline Poleto Bragato.

Writing – review & editing: Jaqueline Poleto Bragato, Flavia Lombardi Lopes, Valéria Marçal Felix de Lima.

References

1. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005; 366: 1561–1577. https://doi.org/10.1016/S0140-6736(05)67629-5 PMID: 16257344

2. Pan American Health Organization (PAHO). Epidemiological Report of the Americas. US11. PAHO; 2017; 2–5. Available: http://iris.paho.org/xmlui/handle/123456789/34112

3. Moreno J, Alvar J. Canine leishmaniasis: Epidemiological risk and the experimental model. Trends Parasitol. 2002; 18: 399–405. https://doi.org/10.1016/S1471-4922(02)02347-4 PMID: 12377257
4. Mancianti F, Gramiccia M, Gradoni L, Pieri S. Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment. Trans R Soc Trop Med Hyg. 1988; 82: 566–7. https://doi.org/10.1016/0395-9203(88)90510-X PMID: 3076714

5. Fisa R, Gállego M, Castillejo S, Aisa MJ, Serra T, Riera C, et al. Epidemiology of canine leishmaniasis in Catalonia (Spain) The example of the Priorat focus. Vet Parasitol. 1999; 83: 87–97. https://doi.org/10.1016/S0304-4017(99)00074-6 PMID: 10392965

6. Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L. Canine leishmaniosis—new concepts and insights on an expanding zoonosis: part one. Trends Parasitol. 2008; 24: 324–330. https://doi.org/10.1016/j.pt.2008.04.001 PMID: 18514028

7. Cabral M, O’Grady J, Alexander J. Demonstration of Leishmania specific cell mediated and humoral immunity in asymptomatic dogs. Parasite Immunol. 1992; 14: 531–9. https://doi.org/10.1111/j.1365-3024.1992.tb00026.x PMID: 1437241

8. Alves CF, de Amorim IFG, Moura EP, Ribeiro RR, Alves CF, Michalick MS, et al. Expression of IFN-γ, TNF-α, IL-10 and TGF-β in lymph nodes associates with parasite load and clinical form of disease in dogs naturally infected with Leishmania (Leishmania) chagasi. Vet Immunol Immunopathol. 2009; 128: 349–358. https://doi.org/10.1016/j.vetimm.2008.11.020 PMID: 1914159

9. Pinelli E, Rutten VP, Bruysters M, Moore PF, Ruitenberg EJ. Compensation for decreased expression of B7 molecules on Leishmania infantum-infected canine macrophages results in restoration of parasite-specific T-cell proliferation and gamma interferon production. Infect Immun. 1999; 67: 237–43. PMID: 9864221

10. Liu G, Abraham E. MicroRNAs in Immune Response and Macrophage Polarization. Arterioscler Thromb Vasc Biol. 2013; 33: 170–177. https://doi.org/10.1161/ATVBAHA.112.300068 PMID: 23325473

11. Bartel DP. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell. 2004; 116(2): 281–97.

12. Solano-Gallego L, Koutinas A, Miro G, Cardoso L, Pennisi MG, Ferrer L, et al. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniasis. Vet Parasitol. 2009; 165: 1–18. https://doi.org/10.1016/j.vetpar.2009.05.022 PMID: 19559536

13. Silva SC, Silva DF, Almeida TC, Perasoli FB, da Silva ATP, da Silva GN, et al. Behavior of two Leishmania infantum strains-evaluation of susceptibility to antimonials and expression of microRNAs in experimentally infected J774 macrophages and in BALB/c mice. Parasitol Res. 2018; 117: 2881–2893. https://doi.org/10.1002/prs.23943317

14. Ghosh J, Bose M, Roy S, Bhattacharyya SN. Leishmania donovani targets dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection. Cell Host Microbe. 2013; 13: 277–288. https://doi.org/10.1016/j.chom.2013.02.005 PMID: 23498953

15. Tiwari N, Kumar V, Gedda MR, Singh AK, Singh VK, Gannavaram S, et al. Identification and Characterization of miRNAs in Response to Leishmania donovani Infection: Delineation of Their Roles in Macrophage Dysfunction. Front Microbiol. 2017; 8: 314. https://doi.org/10.3389/fmicb.2017.00314 PMID: 28303124

16. Pandey RK, Sundar S, Prajapati VK. Differential expression of miRNA regulates T cell differentiation and plasticity during visceral leishmaniasis infection. Front Microbiol. 2016; 7: 1–9. https://doi.org/10.3389/fmicb.2016.00001

17. Bragato JP, Melo LM, Venturin GL, Rebech GT, Garcia LE, Lopes FL, et al. Data on differentially expressed miRNAs in dogs infected with Leishmania infantum. Data Br. Elsevier ; 2018; 17: 218–225. https://doi.org/10.1590/S0100-879X20090400000010 PMID: 12700826

18. Lima VMF, Gonçalves ME, Ikeda FA, Luvizotto MCR, Feitosa MM. Anti-leishmania antibodies in cerebrospinal fluid from dogs with visceral leishmaniasis. Braz J Med Biol Res. 2003; 36: 485–489. https://doi.org/10.1590/S1315-70742003000400010

19. Solano-Gallego L, Koutinas A, Miró G, Cardoso L, Pennisi MG, Ferrer L, et al. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniasis. Vet Parasitol. 2009; 165: 1–18. https://doi.org/10.1016/j.vetpar.2009.05.022 PMID: 19559536

20. Sanches L da C, Martini CC de, Nakamura AA, Santiago MEB, Dolabela de Lima B, Lima VMF de. Natural canine infection by Leishmania infantum and Leishmania amazonensis and their implications for disease control. Rev Bras Parasitol Veterinária. 2016; 25: 465–469. https://doi.org/10.1590/s1884-296120160701 PMID: 27925065

21. Ranasinghe S, Rogers ME, Hamilton JGC, Bates PA, Maingon RDC. A real-time PCR assay to estimate Leishmania chagasi load in its natural sand fly vector Lutzomyia longipalpis. Trans R Soc Trop Med Hyg. 2008; 102: 875–882. https://doi.org/10.1016/j.trstmh.2008.04.003 PMID: 18514028

22. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles G, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013; 14: 128. https://doi.org/10.1186/1471-2105-14-128 PMID: 23586463
23. Kuleshov M V., Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016; 44: W90–W97. https://doi.org/10.1093/nar/gkw377 PMID: 27141961

24. Zhang X, Ng W-L, Wang P, Tian L, Werner E, Wang H, et al. MicroRNA-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNFα. Cancer Res. 2012; 72: 4707–13. https://doi.org/10.1158/0008-5472.CAN-12-0639 PMID: 22836756

25. Liu F, Liu C, Hu X, Shang Y, Wu L. Microrna-21: A positive regulator for optimal production of type I and type III interferon by plasmacytoid dendritic cells. Front Immunol. 2017; 8: 1–14. https://doi.org/10.3389/fimmu.2017.00001

26. Yang N, Li Y, Wang G, Ding Y, Jin Y, Xu Y. Tumor necrosis factor-α inhibits adipogenic and osteogenic differentiation of human periodontal ligament stem cell by inhibiting miR-21/Spyr1 functional axis. Differentiation. 2017; 97: 33–43. https://doi.org/10.1016/j.diff.2017.08.004 PMID: 28946056

27. Sayed D, He M, Hong C, Gao S, Rane S, Yang Z, et al. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of fas ligand. J Biol Chem. 2010; 285: 20281–20290. https://doi.org/10.1074/jbc.M110.109207 PMID: 20404348

28. Wang K, Li PF. Foxo3a regulates apoptosis by negatively targeting miR-21. J Biol Chem. 2010; 285: 16958–16966. https://doi.org/10.1074/jbc.M109.093005 PMID: 20371612

29. Silva KLO, Melo LM, Peroso J, Oliveira BB, Santos PSP dos, Eugênio F de R, et al. CD95 (FAS) and CD178 (FASL) induce the apoptosis of CD4+ and CD8+ cells isolated from the peripheral blood and spleen of naturally infected with Leishmania spp. Vet Parasitol. 2013; 197: 470–476. https://doi.org/10.1016/j.vetpar.2013.07.012 PMID: 23920055

30. Perosso J, Silva KLO, Ferreira Sí de S, Avanço SV, dos Santos PSP, Eugênio F de R, et al. Alteration of sFAS and sFAS ligand expression during canine visceral leishmaniasis. Vet Parasitol. 2014; 205: 417–423. https://doi.org/10.1016/j.vetpar.2014.09.006 PMID: 25260330

31. Carissimi C, Carucci N, Colombo T, Piconese S, Azzalin G, Cipolletta E, et al. miR-21 is a negative modulator of T-cell activation. Biochimie. 2014; 107: 319–326. https://doi.org/10.1016/j.biochi.2014.09.021 PMID: 25304039

32. Mazlooom H, Alizadeh S, Esfahani EN, Razi F, Meshkani R. Decreased expression of microRNA-21 is associated with increased cytokine production in peripheral blood mononuclear cells (PBMCs) of obese type 2 diabetic and non-diabetic subjects. Mol Cell Biochem. 2016; 419: 11–17. https://doi.org/10.1007/s10900-016-2743-9 PMID: 27370645

33. Garchow B, Kiriakidou M. MicroRNA-21 deficiency protects from lupus-like autoimmunity in the chronic graft-versus-host disease model of systemic lupus erythematosus. Clin Immunol. 2016; 162: 100–6. https://doi.org/10.1016/j.clim.2015.11.010 PMID: 26631756

34. Wang Q, Liu S, Tang Y, Liu Q, Yao Y. MPT64 protein from Mycobacterium tuberculosis inhibits apoptosis of macrophages through NF-κB-miRNA21-Bcl-2 pathway. PLoS One. 2014; 9: 1–8. https://doi.org/10.1371/journal.pone.0100949 PMID: 25000291

35. Smigielska-Czepiel K, van den Berg A, Jellema P, SlezaK-Prochazka I, Maat H, van den Bos H, et al. Dual Role of miR-21 in CD4+ T-Cells: Activation-Induced miR-21 Supports Survival of Memory T-Cells and Regulates CCR7 Expression in Naïve T-Cells. PLoS One. 2013; 8: 1–10. https://doi.org/10.1371/journal.pone.0076217 PMID: 24098447

36. Buates S, Matlashewski G. General suppression of macrophage gene expression during Leishmania donovani infection. J Immunol. 2001; 166: 3416–22. https://doi.org/10.4049/jimmunol.166.5.3416 PMID: 11207299

37. Chamekh M. CD40-CD40L Interaction in Immunity Against Protozoan Infections. J Biomed Biotechnol. 2007; 1: 1–6. https://doi.org/10.1155/2007/59430 PMID: 17541468

38. Förster R, Schubel A, Breitfeld D, Kremmer E, Renner-Müller I, Wolf E, et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell. 1999; 99: 23–33. https://doi.org/10.1016/S0092-8674(00)80059-8 PMID: 10520991

39. Zhou X, Mao Y, Zhu J, Meng F, Chen Q, Tao L, et al. TGF-beta promotes colorectal cancer immune escape by elevating B7-H3 and B7-H4 via the miR-155/miR-143 axis. Oncotarget. 2016; 7: 67196–67211. https://doi.org/10.18632/oncotarget.11950 PMID: 27626488

40. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci. 2007; 104: 7080–7085. https://doi.org/10.1073/pnas.0702409104 PMID: 17438277

41. Xiao C, Calado DP, Galler G, Thai T-H, Patterson HC, Wang J, et al. MiR-150 Controls B Cell Differentiation by Targeting the Transcription Factor c-Myb. Cell. 2007; 131: 146–159. https://doi.org/10.1016/j.cell.2007.07.021 PMID: 17923094
42. Reis AB, Teixeira-Caravelho A, Vale AM, Marques MJ, Giunchetti RC, Mayrink W, et al. Isotype patterns of immunoglobulins: Hallmarks for clinical status and tissue parasite density in brazilian dogs naturally infected by Leishmania (Leishmania) chagasi. Vet Immunol Immunopathol. 2006; 112: 102–116. https://doi.org/10.1016/j.vetimm.2006.02.001 PMID: 16621021

43. Schaut RG, Lamb IM, Toepf AJ, Scott B, Mendes-Aguia CO, Coutinho JF V, et al. Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis. J Immunol. 2016; 196: 4100–9. https://doi.org/10.4049/jimmunol.1502678 PMID: 27076677

44. Bezman NA, Chakraborty T, Bender T, Lanier LL. miR-150 regulates the development of NK and iNKT cells. J Exp Med. 2011; 208: 2717–2731. https://doi.org/10.1084/jem.20111386 PMID: 22124110

45. Becker I, Salaíza N, Aguirre M, Delgado J, Carrillo-Carrasco N, Kobeh LG, et al. Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2. Mol Biochem Parasitol. 2003; 130: 65–74. https://doi.org/10.1016/S0166-6851(03)00160-9 PMID: 12946842

46. Nylen S, Maasho K, Söderstrom K, Ilg T, Akuffo H. Live Leishmania promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. Clin Exp Immunol. 2003; 131: 267–274. https://doi.org/10.1046/j.1365-2249.2003.02096.x PMID: 12605699

47. Nylen S, Gautam S. Immunological perspectives of leishmaniasis. J Glob Infect Dis. Wolters Kluwer—Medknow Publications; 2010; 2: 135–146. https://doi.org/10.4103/0974-777X.62876 PMID: 20606969

48. Tian H, Liu C, Zou X, Wu W, Zhang C, Yuan D. MiRNA-194 Regulates Palmitic Acid-Induced Toll-Like Receptor 4 Inflammatory Responses in THP-1 Cells. Nutrients. 2015; 7: 3483–3496. https://doi.org/10.3390/nu7053483

49. Qiu Y-Y, Zhang Y-W, Qian X-F, Bian T. miR-371, miR-138, miR-544, miR-145, and miR-214 could modulate Th1/Th2 balance in asthma through the combinatorial regulation of Runx3. Am J Transl Res. 2017; 9: 3184–3199. PMID: 28804539

50. Corrêa APFL Dossi ACS, de Oliveira Vasconcelos R, Munari DP, de Lima VMF. Evaluation of transforming growth factor β1, interleukin-10, and interferon-γ in male symptomatic and asymptomatic dogs naturally infected by Leishmania (Leishmania) chagasi. Vet Parasitol. 2007; 143: 267–274. https://doi.org/10.1016/j.vetpar.2006.08.023

51. Lage RS, Oliveira GC, Busek SU, Guerra LL, Giunchetti RC, Corrêa-Oliveira R, et al. Analysis of the cytokine profile in spleen cells from dogs naturally infected by Leishmania (Leishmania) chagasi. Vet Immunol Immunopathol. 2007; 115: 135–145. https://doi.org/10.1016/j.vetimm.2006.10.001 PMID: 17097741

52. Yu G, Zha Y, Li H, Wang F, Bian Q, Lai X, et al. Screening plasma miRNAs as biomarkers for renal ischemia-reperfusion injury in rats. Med Sci Monit. 2014; 20: 283–289. https://doi.org/10.12659/MSM.889937 PMID: 24553149

53. Esch KJ, Schaut RG, Lamb IM, Clay G, Morais Lima A, do Nascimento PRP, et al. Activation of Autophagy and Nucleotide-Binding Domain Leucine-Rich Repeat–Containing-Like Receptor Family, Pyrin Domain–Containing 3 Inflammasome during Leishmania infantum–Associated Glomerulonephritis. Am J Pathol. 2015; 185: 2105–2117. https://doi.org/10.1016/j.ajpath.2015.04.017 PMID: 26079813

54. Nicolato R de C, de Abreu RT, Roatt BM, Aguiar-Soares RD de O, Reis LES, Carvalho M das G, et al. Clinical forms of canine visceral Leishmaniasis in naturally Leishmania infantum-infected dogs and related myelogram and hemogram changes. Arez AP, editor. PLoS One. 2013; 8: e82947. https://doi.org/10.1371/journal.pone.0082947 PMID: 24376612

55. De Luna R, Ferrante M, Severino L, Ambrosio R, Plantedosi D, Gradoni L, et al. Decreased lipid fluidity of the erythrocyte membrane in dogs with leishmaniasis-associated anaemia. J Comp Pathol. 2000; 122: 213–6. https://doi.org/10.1053/jcpa.1999.0397 PMID: 10684691

56. Hosokawa K, Kajigaya S, Feng X, Desierto MJ, Fernandez Ibenez MDP, Rios O, et al. A plasma microRNA signature as a biomarker for acquired aplastic anemia. Haematologica. 2017; 102: 69–78. https://doi.org/10.3324/haematol.2016.151076 PMID: 27658437

57. Rasmussen KD, Simmini S, Abreu-Googder C, Bartonicek N, Di Giacomo M, Bilbao-Cortes D, et al. The miR-144/451 locus is required for erythroid homeostasis. J Exp Med. 2010; 207: 1351–1358. https://doi.org/10.1084/jem.20100458 PMID: 20513743

58. Singh AK, Pandey RK, Shaha C, Madhubala R. MicroRNA expression profiling of Leishmania donovani-infected host cells uncovers the regulatory role of MIR30A-3p in host autophagy. Autophagy. 2016; 1–15. https://doi.org/10.1080/15548627.2015.110036